In RA, KMF inhibited the fibroblast growth factor (FGF)/FGFR3/ribosomal S6 kinase 2 (RSK2) axis, thus reducing T cell-mediated cytokine release (e.g., IL-17, IL-21, TNF-α) and fibroblast-like synoviocyte proliferation (47). The gene discussed is RPS6KA3; the disease is rheumatoid arthritis.